Eltrombopag for the treatment of idiopathic thrombocytopenic purpura.

Strategies aimed at stimulating platelet production are a rational approach to the treatment of patients with primary immune thrombocytopenia, as, for many of them, the low platelet count is a consequence of ineffective megakaryopoiesis. Recently, intense clinical trial activity in immune thrombocytopenia has been reported for second-generation thrombopoietic agents. These novel molecules bear no structural resemblance to thrombopoietin, but still bind and activate the thrombopoietin receptor. One of these agents is eltrombopag (formerly SB497115), an orally available, small organic compound. Randomized trials have shown the short-term efficacy of eltrombopag in elevating the platelet count of most adult patients with immune thrombocytopenia unresponsive to at least one standard treatment. No significant adverse events were observed, but long-term safety data are still lacking. Ongoing studies will reveal the potential of this agent in the management of immune thrombocytopenia for long-term maintenance therapy, as well as its relative benefit compared with standard-of-care treatment.
AuthorsRoberto Stasi
JournalExpert review of hematology (Expert Rev Hematol) Vol. 1 Issue 2 Pg. 145-52 (Dec 2008) ISSN: 1747-4094 [Electronic] England
PMID21082919 (Publication Type: Journal Article, Review)
Chemical References
  • Benzoates
  • Hydrazines
  • Pyrazoles
  • eltrombopag
  • Benzoates (pharmacology, therapeutic use)
  • Humans
  • Hydrazines (pharmacology, therapeutic use)
  • Purpura, Thrombocytopenic, Idiopathic (blood, drug therapy, immunology)
  • Pyrazoles (pharmacology, therapeutic use)
  • Thrombopoiesis (drug effects)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: